Imidapril
Alternative Names: Novarok; SH 6366; TA 6366; TanatrilLatest Information Update: 10 Dec 2025
At a glance
- Originator Tanabe Seiyaku
- Developer G.L. Pharma; Gerolymatos Group; Tanabe Pharma Corporation; Trinity-Chiesi Pharmaceuticals
- Class Antihypertensives; Heart failure therapies; Imidazolidines; Small molecules
- Mechanism of Action ACE inhibitors
-
Orphan Drug Status
Yes - Diabetic nephropathies
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Diabetic nephropathies; Hypertension